Notable Investments
170 Life Science Venture Investments 9 IPOs Since 2013
6 Drugs Approved since 2008
Delphi Ventures was founded over 25 years ago as one of the first venture capital firms to focus exclusively on investing in life sciences companies.

Alder BioPharmaceuticals

Bringing new therapies to the treatment of migraine, rheumatoid arthritis, and other conditions.

View Website

Calithera Biosciences

Discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer.

View Website

Karyopharm Therapeutics

Clinical-stage pharmaceutical company focused on discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases.

View Website

OncoMed Pharmaceuticals

Development-stage biotechnology company dedicated to improving cancer treatment by discovering and developing monoclonal antibodies and other agents that target the biologic pathways critical to tumor initiating cells, also known as "cancer stem cells". They are leveraging their understanding of these tumor initiating cells to discover and develop novel therapeutics that could provide important alternatives for the treatment of cancer.

View Website

PTC Therapeutics

Applying its expertise in RNA biology and drug development to pioneer novel oral treatments for patients living with serious and life-threatening conditions.

View Website

Relypsa

Focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases.

View Website

Tandem Diabetes Care

Novel technology in the development of a medical device for insulin administration.

View Website

TriVascular

Developing novel endovascular repair devices to treat aortic aneurisms.

View Website

Cardeas Pharma Corp

Early phase development of inhaled antibiotics to treat serious, hospital-acquired respiratory infections with highly antibiotic-resistant organisms. By combining novel formulations of proven antibiotics with cutting edge drug delivery technology, Cardeas is addressing significant unmet medical needs in the critical-care setting.

View Website

Labcyte

Instrumentation using focused acoustic energy to accurately dispense very small quantities of high-value fluids for pharmaceutical research.

View Website

Ivantis

Minimally invasive technology to treat ophthalmic disease.

View Website

Senseonics

Focused on the development and commercialization of the first fully implantable, long term continuous glucose monitoring system.

View Website

Alexza Pharmaceuticals

Inhaled therapies for acute and intermittent conditions employing a device that rapidly delivers pure drug.

View Website

Aegea Medical

Medical device technology for the in-office treatment of excessive menstrual bleeding.

View Website

Astute Medical

Dedicated to improving the diagnosis of high-risk medical Conditions and diseases through the identification and validation of protein biomarkers that can serve as the basis for novel in vitro diagnostic tests.

View Website

EBR Systems

Wireless cardiac stimulation.

View Website

ForSight VISION5

Developing sustained release non-invasive drug delivery designed to lower intraocular pressure.

View Website

Nuvesse, MD

Advanced skin therapy born out of wound healing science that is clinically tested to go deeper and faster, accelerating skin's natural rejuvenation.

View Website

Revance Therapeutics

Focused on the development, manufacturing and commercialization of novel botulinum toxin products across multiple aesthetic and therapeutic applications.

View Website

Sequent Medical

Developing innovative catheter-based neurovascular technologies.

View Website

Sotera Wireless

Dedicated to development, marketing and sale of a new generation of comprehensive vital signs monitoring.

View Website

SynergEyes

Contact lenses that combine the superior vision of a gas permeable lens with the comfort and ease of wear of a soft contact lens.

View Website

Managing Partners

Managing Partner

Deepa Pakianathan

Deepa Pakianathan

Deepa is a Managing Member at Delphi Ventures and leads all of the firm’s biotechnology investment activities.

She currently serves on the boards of Alder Biopharmaceuticals (Nasdaq:ALDR), Alexza Pharmaceuticals (Nasdaq:ALXA), Calithera Biosciences (Nasdaq: CALA), ForSight:Vision5, Karyopharm Therapeutics (Nasdaq:KPTI) and Oncomed Pharmaceuticals (Nasdaq:OMED).

Deepa previously served on the boards of Salmedix (acquired by Cephalon), Ilypsa (acquired by Amgen), PTC Therapeutics (Nasdaq:PTCT) and Relypsa(Nasdaq:RYLP). She also led the investments in Cardeas Pharma, KAI Pharmaceuticals (acquired by Amgen), and a PIPE investment in Seattle Genetics (Nasdaq:SGEN).

Deepa joined Delphi in 2001 to build and lead the firm’s biotechnology investment practice which focuses on drug discovery and development platform technologies that have resulted in multiple novel drugs, including six that are commercially marketed.

Prior to joining Delphi, Deepa was a Vice President in the healthcare group at J.P. Morgan where she was involved in several large healthcare M&A transactions and led public offerings for biotechnology companies that raised over $9 billion. Prior to that, she was a biotechnology research analyst at Genesis Merchant Group. She worked as a postdoctoral scientist in the Immunology Department at Genentech Corporation from 1993 to 1997.

She serves as Vice-Chair of the San Francisco Conservatory of Music’s Board of Trustees.

Deepa received her Ph.D. and MS from Wake Forest University and her MSc and BSc from the University of Bombay.

Managing Partner

Doug Roeder

Doug Roeder

Doug joined Delphi Ventures as an Associate in 1998 and became a Partner in 2000. His primary investment focus at Delphi is on medical devices and diagnostics.

Prior to joining Delphi, Doug was an Associate with Alex. Brown's Healthcare Investment Banking Group in San Francisco. While at Alex. Brown Doug assisted in the execution of over a dozen financing and merger transactions involving both Fortune 500 and venture-backed medical technology companies, including a number of Delphi portfolio companies.

Previously, Doug was with Putnam Associates, a consulting firm focused on the biopharmaceutical industry, where his primary role was to develop and implement a strategy for the launch of a leading biotech drug.

CFO, Partner

Matthew Potter

Matthew Potter

As Chief Financial Officer, Matt has primary responsibility for Delphi's accounting and reporting. He also leads the firm's administrative and operational efforts including investor relations, human resources, information technology, legal affairs and portfolio company assistance.

Prior to joining Delphi Ventures in 2000, Matt spent three years as Controller at Bluecurve, Inc., an enterprise performance management software startup. He held various reporting and operational duties until the company's acquisition by Red Hat, Inc. (NYSE: RHT).

Prior to Bluecurve, he spent six years in public accounting with former Arthur Andersen managers Schorno, Murray & Co. providing audit, tax and business advisory services to private companies, real estate investment partnerships, and not-for-profit organizations.

Matt is a Certified Public Accountant and is a member of the California State Board of Accountants. He is a member of a NVCA CFO Task Force and has served on the West Coast Chapter Board of Directors of the Private Equity CFO Association (PECFOA).

Partner Emeritus

James Bochnowski

Jim founded Delphi Ventures in 1988. His focus is on medical devices and biotechnology.

Jim began investing in medical companies in 1981 after co-founding Technology Venture Investors, a private venture capital partnership. Since 1984, he has focused exclusively on healthcare investments.

From 1976 to 1980, Jim was with Shugart Associates, a venture-backed disk drive company. As President and CEO, he led Shugart to increasing profitability, with annual revenues growing from $13 million to $200 million. Shugart was acquired by Xerox in 1979.

From 1972 to 1976, Jim was a general partner with Donaldson Lufkin & Jenrette's (DLJ) venture capital arm, the Sprout Capital Group. Prior to that, he served as a securities analyst with DLJ.

Trained as an aerospace engineer at MIT, Jim served as an Army officer and a missile systems engineer with the U.S. Army Missile Intelligence Directorate, serves on the Board of Overseers of the Hoover Institution at Stanford University and is a member of the Harvard School of Public Health's Health Policy and Management Executive Council. Jim was a director of the Western Association of Venture Capital.

Operations Team

Operations Team

From left to right

Cassandrea Miller

Executive Assistant

Olivia Liao

Controller

Cynthia Banfield

Staff Accountant

Delphi Ventures
3000 Sand Hill Rd, Bldg 1 #135
Menlo Park, CA 94025
+1 (650) 854-9650
Map/Directions